Montelukast can reduce the severity and extent of atopic dermatitis

Journal of Paediatrics and Child Health

Volumn 49, Issue 5, 2013, Pages 412-415

  Holme, Harriet ^a   Winckworth, Lucinda C ^a  

^a WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

atopic dermatitis; dermatology; general paediatrics; montelukast

Indexed keywords

MONTELUKAST;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; CASE REPORT; CHILD; DISEASE SEVERITY; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ACETATES; ASTHMA; CHILD; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HUMANS; INFORMATION STORAGE AND RETRIEVAL; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES;

EID: 84877301965     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12202     Document Type: Article

References (15)

1. Pei AY, Chan HH, Leung TF,. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr. Allergy Immunol. 2001; 12: 154-158.
2. Ehlayel MS, Bener A, Sabbah A,. Montelukast treatment in children with moderately severe atopic dermatitis. Eur. Ann. Allergy Clin. Immunol. 2007; 39: 232-236.
3. Hon KL, Leung TF, Ma KC, Wong Y, Fok TF,. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J. Dermatolog. Treat. 2005; 16: 15-18.
4. Centre of Evidence-Based Medicine. 'Levels of Evidence' document. 2009. Available from: http://www.cebm.net/index.aspx?o=1025 [accessed 26 February 2012].
5. Centre for Evidence Based Medicine. Critically Appraised Topics tool 'CATmaker'. Available from: http://www.cebm.net/index.aspx?o=1216 [accessed 1 October 2011].
6. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A,. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
7. Schmitt J, Langan S, Williams HC,. What are the best outcome measurements for atopic eczema? A systematic review. J. Allergy Clin. Immunol. 2007; 120: 1389-1398.
8. Cai C, Zhou MX, Li YP, Chen CS,. [Association of leukotriene gene polymorphisms with response to antileukotriene treatment in patients with asthma]. Zhonghua Jie He He Hu Xi Za Zhi 2011; 34: 362-366.
9. Kotani H, Kishi R, Mouri A, et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. J. Clin. Pharm. Ther. 2011; 37: 112-116.
10. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB,. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br. J. Dermatol. 2007; 157: 645-648.
11. Capella GL, Grigerio E, Altomare G,. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur. J. Dermatol. 2001; 11: 209-213.
12. Rahman ML, Choudhury AM, Islam MM,. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med. J. 2006; 15: 85-88.
13. Friedmann PS, Palmer R, Tan E, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin. Exp. Allergy. 2007; 37: 1536-1540.
14. Veien NK, Busch-Sorensen M, Stausbol-Gron B,. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2005; 53: 147-149.
15. Ehlayel MS, Bener A,. Does montelukast reduce the treatment cost in children with moderately severe atopic dermatitis? Curr. Pediatr. Res. 2008; 12: 1-4.